Literature DB >> 12742114

Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry.

Heiko Schneider1, Lan Ma, Hansruedi Glatt.   

Abstract

Caffeine is metabolised in humans primarily by cytochromes P450 1A2 and 2A6, xanthine dehydrogenase/oxidase, and N-acetyltransferase 2. The activities of these enzymes show a large variation due to genetic polymorphisms and/or induction by xenobiotics. Ratios of different caffeine metabolites in urine or other body fluids are frequently used to characterise the individual/actual activity of these enzymes. The common analytical method involves extensive sample preparation, followed by HPLC-UV. The presence of numerous other UV-absorbing chemicals in body fluids affects the sensitivity and selectivity of this method. We have developed an HPLC-electrospray-MS-MS method for the determination of 11 caffeine metabolites and two internal standards after a simple, extractionless preparation. Blank urine, obtained after 5 days on a methylxanthine-free diet, contained small amounts of some caffeine metabolites, but no other components producing any confounding signals. Eleven metabolites and internal standards were recovered at 90 to 110% after addition to the blank urine (0.1 to 2.5 micro M in the final sample involving a 20-fold dilution of urine) in the 0.1-2.5 micro M concentration range. Other metabolites, 5-acetylamino-6-amino-3-methyluracil (AAMU) and 5-acetylamino-6-formylamino-3-methyluracil (AFMU), were detected with similar recovery and precision, but required higher concentrations (3 to 30 micro M). AFMU was completely converted into AAMU by a short alkalisation of urine. The method was explored in six healthy individuals after consuming coffee (4 mg caffeine per kg body mass). These experiments demonstrated the simplicity, high sensitivity and selectivity of the method under conditions used for phenotyping.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742114     DOI: 10.1016/s1570-0232(03)00065-5

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Correction of accurate mass measurement for target compound verification by quadrupole time-of-flight mass spectrometry.

Authors:  Harald C Köfeler; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2005-03       Impact factor: 3.109

2.  Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.

Authors:  Alexander Jetter; Martina Kinzig-Schippers; Michael Illauer; Robert Hermann; Katharina Erb; Jürgen Borlak; Helga Wolf; Gillian Smith; Ingolf Cascorbi; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2004-01-28       Impact factor: 2.953

3.  Development and validation of a standardized protocol to monitor human dietary exposure by metabolite fingerprinting of urine samples.

Authors:  Gaëlle Favé; Manfred Beckmann; Amanda J Lloyd; Shaobo Zhou; Graham Harold; Wanchang Lin; Kathleen Tailliart; Long Xie; John Draper; John C Mathers
Journal:  Metabolomics       Date:  2011-02-23       Impact factor: 4.290

4.  Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.

Authors:  Peter E Haroldsen; Marvin R Garovoy; Donald G Musson; Huiyu Zhou; Laurie Tsuruda; Boyd Hanson; Charles A O'Neill
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

5.  Determination of Urinary Caffeine Metabolites as Biomarkers for Drug Metabolic Enzyme Activities.

Authors:  Hyeong Jun Kim; Min Sun Choi; Shaheed Ur Rehman; Young Seok Ji; Jun Sang Yu; Katsunori Nakamura; Hye Hyun Yoo
Journal:  Nutrients       Date:  2019-08-19       Impact factor: 5.717

6.  Effects of baicalin on oral pharmacokinetics of caffeine in rats.

Authors:  Keumhan Noh; Mahesh Raj Nepal; Ki Sun Jeong; Sun-A Kim; Yeon Ji Um; Chae Shin Seo; Mi Jeong Kang; Pil-Hoon Park; Wonku Kang; Hye Gwang Jeong; Tae Cheon Jeong
Journal:  Biomol Ther (Seoul)       Date:  2015-03-01       Impact factor: 4.634

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.